North Immunology is going public in a reverse merger with Aethlon Medical. With eczema as the lead indication, the inflammation and immunology biotech aims to show its bispecific antibody offers efficacy and tolerability advantages over Sanofi’s immune disorder juggernaut, Dupixent.
The post North Immunology Reverse Merger Comes With $180M for Next-Gen Inflammation Drug appeared first on MedCity News.
